IL-23, His-Tag Recombinant
Recombinant human IL-23 (interleukin 23), encompassing amino acids 20-189. The construct includes a C-terminal His-tag. This protein was affinity purified.
>95%, as determined by SDS-PAGE and HPLC
Recombinant IL-23A was lyophilized from 0.2 µm filtered PBS solution pH 7.4
IL-23 (interleukin 23) is a cytokine involved in inflammation. It is composed of two subunits, IL-12-B (or IL-12p40) and IL-23A (or IL-23p19) and binds to the IL-23 receptor. It supports Th17 T cell maintenance, expansion and cytokine release, NK cell IFNγ (interferon γ) secretion and increased ADCC (antibody-dependent cellular cytotoxicity) and CD4+ T cell proliferation. Il-23 is produced and secreted by activated dendritic cells, macrophages, B cells and γδ T cells. Excessive production of this cytokine can lead to autoimmune disorders, such as psoriasis, and even cancer. Ustekinumab (sold under the brand name STELARA®) and guselkumab (sold under the brand name Tremfya®) are two commercial monoclonal antibodies targeting IL-23, designed for the treatment of Crohn’s disease, ulcerative colitis, plaque and arthritic psoriasis. The success of these two drugs indicates the relevance of this cytokine in human health and disease, making it a valuable therapeutic target.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.